Frontage is delighted to announce Mr. Henry Gao's appointment as President of Asia Pacific. With over 26 years of extensive expertise in overseeing finance, audit, investment, project management, compliance, and board functions, Mr. Gao brings invaluable experience. Additionally, he holds significant proficiency in spearheading IPOs and M&A ventures. Serving as a board member from 2018 to 2022, Mr. Gao now assumes the role of overseeing the Group's operations across the Asia-Pacific region in his capacity as President.
Dr. Abdul Mutlib, CEO of Frontage Holdings Corporation, expressed enthusiasm about Henry's return, stating, "I'm thrilled to have Henry back as our President for Asia Pacific. His extensive background in executive roles, especially within biotechnology and CRO domains, positions him ideally to lead Frontage's operations in the Asia Pacific region. I'm confident that his leadership will propel Frontage to be a leading CRO platform in China and beyond".
In response to his appointment, Mr. Gao conveyed, "I'm honored to rejoin Frontage. I strongly believe that my extensive leadership background, particularly within the CRO sector, will significantly bolster Frontage's ability to deliver exceptional client service to pharmaceutical companies and R&D institutions. I eagerly anticipate collaborating with Frontage's Asia Pacific team, alongside colleagues in North America and globally, aiming to elevate Frontage to new heights".